Stephens initiated coverage of C4 Therapeutics (CCCC) with an Equal Weight rating and $4 price target The firm is adding to its Biotechnology research coverage with a focus on targeted protein ...
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the ...